Nonalcoholic Fatty Liver Disease (NAFLD) for Primary Care Providers: Beyond the Liver

被引:10
作者
Godinez-Leiva, Eddison [1 ]
Bril, Fernando [1 ,2 ,3 ]
机构
[1] Univ Alabama Birmingham, Div Endocrinol Diabet & Metab, Birmingham, AL 35233 USA
[2] Univ Florida, Dept Med, Gainesville, FL USA
[3] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35233 USA
关键词
NAFLD; steatohepatitis; NASH; T2DM; insulin resistance; liver; MAGNETIC-RESONANCE ELASTOGRAPHY; HEPATIC TRIGLYCERIDE CONTENT; IMPAIRED INSULIN-CLEARANCE; TYPE-2; DIABETES-MELLITUS; LIFE-STYLE MODIFICATION; CARDIOVASCULAR-DISEASE; HEPATOCELLULAR-CARCINOMA; TRANSIENT ELASTOGRAPHY; BARIATRIC SURGERY; CONTROLLED-TRIAL;
D O I
10.2174/1573402116999201209203534
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Nonalcoholic fatty liver disease (NAFLD) has consolidated as a major public health problem, affecting-25% of the global population. This percentage is significantly higher in the setting of obesity and/or type 2 diabetes. The presence of NAFLD is associated with severe liver complications, such as nonalcoholic steatohepatitis (NASH; i.e., presence of inflammation and necrosis), cirrhosis and hepatocellular carcinoma. However, the majority of these patients die of cardiovascular disease. For this reason, management of this condition requires a multidisciplinary team, where primary care providers are at center stage. However, important misconceptions remain among primary care providers, preventing them from appropriately approach these patients. Nonalcoholic fatty liver disease should be understood as part of a systemic disease characterized for abnormal accumulation of fat in tissues other than the adipose tissue. This, in turn, produces dysfunction of those organs or tissues (process sometimes referred to as lipotoxicity). Therefore, due to the systemic nature of this condition, it should not surprise that NAFLD is closely related to other metabolic conditions. This review will focus on the extrahepatic manifestations of NAFLD and its metabolic and cardiovascular implications. We believe these are the most important issues primary care providers should understand in order to effectively manage these complicated patients. In addition, we have provided a simple and straightforward approach to the diagnosis and treatment of patients with NAFLD and/or NASH. We hope this review will serve as a guide for primary care providers to approach their patients with NAFLD.
引用
收藏
页码:94 / 111
页数:18
相关论文
共 166 条
  • [1] Mortality in Nonalcoholic Fatty Liver Disease: Clues from the Cremona Study
    Adams, Leon A.
    [J]. HEPATOLOGY, 2011, 54 (01) : 6 - 8
  • [2] NAFLD as a Risk Factor for the Development of Diabetes and the Metabolic Syndrome: An Eleven-Year Follow-up Study
    Adams, Leon A.
    Waters, Oliver R.
    Knuiman, Matthew W.
    Elliott, Robert R.
    Olynyk, John K.
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 (04) : 861 - 867
  • [3] Weight and Metabolic Outcomes 12 Years after Gastric Bypass
    Adams, Ted D.
    Davidson, Lance E.
    Litwin, Sheldon E.
    Kim, Jaewhan
    Kolotkin, Ronette L.
    Nanjee, M. Nazeem
    Gutierrez, Jonathan M.
    Frogley, Sara J.
    Ibele, Anna R.
    Brinton, Eliot A.
    Hopkins, Paul N.
    McKinlay, Rodrick
    Simper, Steven C.
    Hunt, Steven C.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (12) : 1143 - 1155
  • [4] Novel Plasma Biomarkers Associated With Liver Disease Severity in Adults With Nonalcoholic Fatty Liver Disease
    Ajmera, Veeral
    Perito, Emily R.
    Bass, Nathan M.
    Terrault, Norah A.
    Yates, Katherine P.
    Gill, Ryan
    Loomba, Rohit
    Diehl, Anna Mae
    Aouizerat, Bradley E.
    [J]. HEPATOLOGY, 2017, 65 (01) : 65 - 77
  • [5] Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts
    Alexander, Myriam
    Loomis, A. Katrina
    van der Lei, Johan
    Duarte-Salles, Talita
    Prieto-Alhambra, Daniel
    Ansell, David
    Pasqua, Alessandro
    Lapi, Francesco
    Rijnbeek, Peter
    Mosseveld, Mees
    Waterworth, Dawn M.
    Kendrick, Stuart
    Sattar, Naveed
    Alazawi, William
    [J]. BMC MEDICINE, 2019, 17 (1)
  • [6] Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year-community study
    Allen, Alina M.
    Therneau, Terry M.
    Larson, Joseph J.
    Coward, Alexandra
    Somers, Virend K.
    Kamath, Patrick S.
    [J]. HEPATOLOGY, 2018, 67 (05) : 1726 - 1736
  • [7] The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD
    Angulo, Paul
    Hui, Jason M.
    Marchesini, Giulio
    Bugianesi, Ellisabetta
    George, Jacob
    Farrell, Geoffrey C.
    Enders, Felicity
    Saksena, Sushma
    Burt, Alastair D.
    Bida, John P.
    Lindor, Keith
    Sanderson, Schuyler O.
    Lenzi, Marco
    Adams, Leon A.
    Kench, James
    Therneau, Terry M.
    Day, Christopher P.
    [J]. HEPATOLOGY, 2007, 45 (04) : 846 - 854
  • [8] Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
    Armstrong, Matthew James
    Gaunt, Piers
    Aithal, Guruprasad P.
    Barton, Darren
    Hull, Diana
    Parker, Richard
    Hazlehurst, Jonathan M.
    Guo, Kathy
    Abouda, George
    Aldersley, Mark A.
    Stocken, Deborah
    Gough, Stephen C.
    Tomlinson, Jeremy W.
    Brown, Rachel M.
    Huebscher, Stefan G.
    Newsome, Philip N.
    [J]. LANCET, 2016, 387 (10019) : 679 - 690
  • [9] Combined Effect of Nonalcoholic Fatty Liver Disease and Impaired Fasting Glucose on the Development of Type 2 Diabetes A 4-year retrospective longitudinal study
    Bae, Ji Cheol
    Rhee, Eun Jung
    Lee, Won Young
    Park, Se Eun
    Park, Cheol Young
    Oh, Ki Won
    Park, Sung Woo
    Kim, Sun Woo
    [J]. DIABETES CARE, 2011, 34 (03) : 727 - 729
  • [10] Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2 Diabetes
    Barb, Diana
    Bril, Fernando
    Kalavalapalli, Srilaxmi
    Cusi, Kenneth
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2019, 104 (08) : 3327 - 3336